natgillin/translations-raw huggingface dataset:
The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the batch number.
Minimalne podatke koji se trebaju unijeti u sigurnosno izvješće o pojedinačnom slučaju, kako bi se omogućila procjena i identifikacija primijenjenog cjepiva za svaku osobu, uključujući zaštićeno ime, proizvođača cjepiva i serijski broj.
The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the batch number.
Minimalne pojedinosti koje treba prijaviti u pojedinačnim sigurnosnim prikazima slučaja radi omogućavanja procjene i identifikacije cjepiva danog svakom pacijentu, uključujući zaštićeno ime, proizvođača cjepiva i serijski broj.
The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the batch number.
Minimalni podaci koje treba prenijeti u sigurnosnom izvješću o pojedinom slučaju radi omogućavanja procjene i identifikacije cjepiva primijenjenog na svaku osobu uključuju zaštićeno ime, proizvođača cjepiva i broj serije.
The minimal inhibitory concentration (MIC) of tylvalosin for M. gallisepticum ranges from 0.007 to
Minimalna inhibitorna koncentracija (MIK) tilvalozina za bakteriju M. gallisepticum kreće se u rasponu od 0,007 do
The minimal specific activity is 3,700 MBq Copper-64/micrograms of Copper at the expiry date and time.
Minimalna specifična aktivnost je 3.700 MBq bakra-64/mikrogram bakra na datum i vrijeme isteka roka valjanosti.
The minimal specific activity is 3,700 MBq Copper-64/micrograms of Copper at the expiry date and time.
Minimalna specifična aktivnost je 3700 MBq bakra-64/mikrogram bakra na datum i vrijeme isteka roka valjanosti.
The minimal washout period in clinical trials was of 4 weeks.
Minimalno razdoblje ispiranja u kliničkim ispitivanjima iznosilo je 4 tjedna.
The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36%.
Minimalna alveolarna koncentracija (MAC) sevoflurana u pasa je 2,36%.
The minimum anti-HPV titer that confers protective efficacy has not been determined.
Minimalni anti-HPV titar koji osigurava djelotvornu zaštitnu nije utvrđen.
The minimum distribution rate is :
Minimalna distribucijska stopa je:
The minimum recommended dose is 6.4 mg dinotefuran/kg body weight, 0.6 mg pyriproxyfen/kg body weight and 46.6 mg permethrin/kg body weight, equivalent to 0.12 ml of the veterinary medicinal product per kg body weight.
Minimalna preporučena doza iznosi 6,4 mg dinotefurana/kg tjelesne težine, 0,6 mg piriproksifena/kg tjelesne težine i 46,6 mg permetrina/kg tjelesne težine, što je jednako 0,12 ml veterinarsko- medicinskog proizvoda po kg tjelesne težine.
The minimum recommended dose is 6.4 mg dinotefuran/kg body weight, 0.6 mg pyriproxyfen/kg body weight and 46.6 mg permethrin/kg body weight, equivalent to 0.12 ml of the veterinary medicine per kg body weight.
Minimalna preporučena doza iznosi 6,4 mg dinotefurana/kg tjelesne težine, 0,6 mg piriproksifena/kg tjelesne težine i 46,6 mg permetrina/kg tjelesne težine, što je jednako 0,12 ml veterinarsko- medicinskog proizvoda po kg tjelesne težine.
The mist-release button must be pressed firmly all the way in, to release the mist through the nozzle - see picture c.
Tipka za ispuštanje maglice mora se čvrsto pritisnuti skroz do kraja kako bi otpustila maglicu kroz raspršivač – pogledajte sliku c.
The mitochondrial membrane is more readily permeable for carglumic acid than for N- acetylglutamate
Mitohondrijska membrana bolje propušta karglumatnu kiselinu nego N-acetilglutamat.
The mixed administration of UNISTRAIN PRRS and ERYSENG PARVO should only be used when vaccinating animals prior to mating.
Miješana primjena UNISTRAIN PRRS i ERYSENG PARVO može se koristiti samo prilikom cijepljenja životinja prije parenja.
The mixed vaccine can either be stored in a refrigerator (2°C - 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be allowed to reach room temperature (for a minimum of 15 minutes) before each withdrawal.
Pripremljeno cjepivo može se čuvati ili u hladnjaku (2°C - 8°C) ili na sobnoj temperaturi koja ne prelazi 25°C. Ako se pripremljeno cjepivo čuva u hladnjaku, prije svake primjene treba pričekati da se zagrije na sobnu temperaturu (najmanje 15 minuta).
The mixed vaccine can either be stored in a refrigerator (2°C - 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be brought to room temperature (allow a minimum of 15 minutes) before each withdrawal.
Pripremljeno cjepivo može se čuvati ili u hladnjaku (2°C - 8°C) ili na sobnoj temperaturi koja ne prelazi 25°C. Ako se pripremljeno cjepivo čuva u hladnjaku, prije svake primjene treba pričekati da se zagrije na sobnu temperaturu (najmanje 15 minuta).
The mixed vaccine can either be stored in a refrigerator (2°C – 8°C) or at room temperature (25°C – 30°C).
Pripremljeno cjepivo može se čuvati ili u hladnjaku (2°C-8°C) ili na sobnoj temperaturi (25°C-30°C).
The mixed vaccine can either be stored in a refrigerator (2°C – 8°C) or at room temperature (25°C – 30°C).
Pripremljeno cjepivo se može čuvati ili u hladnjaku (2°C-8°C) ili na sobnoj temperaturi (25°C-30°C).
The mixed vaccine is a whitish emulsion.
Pripremljeno cjepivo je bjelkasta emulzija .
The mixed vaccine is a whitish to to yellowish homogeneous milky liquid emulsion.
Pripremljeno cjepivo je bjelkasta do žućkasta mliječna homogena emulzija.
The mixed vaccine is a whitish to yellowish homogeneous milky liquid emulsion.
Pripremljeno cjepivo je bjelkasta do žučkasta mliječna homogena emulzija.
The mixed vaccines should be administered by subcutaneous injection.
Pomiješano cjepivo primjenjuje se subkutano.
The mixed vaccines should be administered by subcutaneous injection.
Pomiješano cjepivo treba primijeniti subkutano.
The mixed vaccines should be injected immediately via the subcutaneous route.
Pomiješana cjepiva trebaju se odmah subkutano injicirati.
The mixing may be done with one teaspoonful (approximately 5 mL) of milk for children weighing up to 5 kg, or with a tablespoonful (approximately 15 mL) of milk or fruit juice for children weighing more than 5 kg, delivered in a baby’s bottle.
Za miješanje se može uzeti jedna puna čajna žličica (oko 5 ml) mlijeka za djecu tešku do 5 kg ili jedna puna jušna žlica (oko 15 ml) mlijeka ili voćnog soka za djecu težu od 5 kg, dano putem dječje bočice.
The mixture can also be administered via a nasogastric tube (CH8 or greater).
Mješavina se može primijeniti i putem nazogastrične sonde (CH8 ili veće).
The mixture is fed to the infant or young child.
Mješavinom treba nahraniti dojenče ili mlađe dijete.
The mixture should be administered immediately after preparation.
Mješavina se mora konzumirati odmah nakon pripreme.
The mixture should then be well shaken until the powder is completely dissolved prior to administration.
Prije primjene, mješavinu treba dobro protresti sve dok se prašak potpuno ne otopi.
The MMR rate at 12, 24, 36, 48, 60 and 72 months is presented in Table 5.
Stopa MMR-a u 12., 24., 36., 48., 60. i 72. mjesecu prikazana je u Tablici 5.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Postupci mobilizacije i afereze trebaju se provoditi u suradnji s onkološko-hematološkim centrom s prihvatljivim iskustvom u tim postupcima, u kojem se krvotvorne progenitorske stanice mogu pratiti na ispravan način.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Postupke mobilizacije i afereze potrebno je provesti u suradnji s onkološko-hematološkim centrom s prihvatljivim iskustvom u tom području u kojem se praćenje progenitorskih krvotvornih stanica može provoditi na ispravan način.
The mode of action of itraconazole is based on its highly selective binding ability for fungal cytochrome P- 450 iso-enzymes.
Način djelovanja itrakonazola temelji se na izrazito selektivnoj sposobnosti vezivanja za gljivične izoenzime citokrom P-450.
The mode of action of itraconazole is based on its highly selective binding ability for fungal cytochrome P-450 isoenzymes.
Način djelovanja itrakonazola temelji se na izrazito selektivnoj sposobnosti vezivanja za gljivične izoenzime citokrom P-450.
The mode of action of thiazides is through inhibition of the Na+Cl- symporter perhaps by competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.
Način djelovanja tiazida je kroz inhibiciju Na+Cl- simportera, pretpostavlja se nadmetanjem za mjesto vezanja Cl-, čime se utječe na mehanizme reapsorpcije elektrolita: direktnim povećanjem izlučivanja natrija i klorida u otprilike podjednakoj mjeri, a indirektno smanjenjem volumena plazme putem ovog diuretskog djelovanja, s posljedičnim povećanjem aktivnosti renina u plazmi, lučenja aldosterona i gubitka kalija mokraćom te sniženja kalija u serumu.
The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Način djelovanja sugerira da bi učinci L-dope, dopaminergičkih agonista i antikolinergika mogli biti pojačani istodobnom primjenom NMDA-antagonista poput memantina.
The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Način djelovanja sugerira da bi učinci L-dope, dopaminergičkih agonista i antikolinergika mogli biti pojačani pri istodobnom liječenju NMDA-antagonistima poput memantina.
The model- predicted duloxetine steady state plasma concentrations in paediatric patients were mostly within the concentration range observed in adult patients.
Modelom predviđene koncentracije duloksetina u plazmi u stanju dinamičke ravnoteže u pedijatrijskih bolesnika uglavnom su bile unutar raspona koncentracija primijećenih u odraslih bolesnika.
The modeled treatment effect for the percent change in urine KS, compared to placebo, was -40.7 % (CI95, -49.0, -32.4; p<0.0001) for the 2 mg/kg per week regimen.
Modelirani učinak liječenja za postotak promjene KS-a u mokraći u usporedbi s placebom bio je -40,7 % (CI95, -49,0, -32,4; p<0,0001) za režim doze od 2 mg/kg/tjedno.
The modeled treatment effect in stairs climbed per minute, compared to placebo, was 1.1 stairs/minute (CI95, -2.1, 4.4; p=0.4935) for the 2 mg/kg per week regimen.
Modelirani učinak liječenja na broj prijeđenih stepenica u minuti u usporedbi s placebom bio je 1,1 stepenica/minuti (CI95, -2,1, 4,4; p=0,4935) za režim doziranja od 2 mg/kg/tjedno.
The modeled treatment effect in the distance walked in 6 minutes, compared to placebo, was 22.5 m (CI95, 4.0, 40.9; p=0.0174) for the 2 mg/kg per week regimen.
Modelirani učinak liječenja na udaljenost prehodanu za 6 minuta u usporedbi s placebom bio je 22,5 m (CI95, 4,0, 40,9; p=0,0174) za režim doziranja od 2 mg/kg/tjedno.
The moderate number (approximately 450) of prospectively collected pregnancies exposed to infliximab with known outcomes, including a limited number (approximately 230) exposed during the first trimester, does not indicate unexpected effects on pregnancy outcome.
Prospektivno prikupljeni podaci na umjereno velikom broju (približno 450) trudnoća izloženih infliksimabu u kojih je ishod bio poznat, uključujući ograničeni broj (približno 230) trudnoća izloženih tijekom prvog tromjesečja, nisu pokazali neočekivane učinke na ishod trudnoće.
The modified intent-to-treat (MITT) group included 465 allogeneic HSCT recipients with 45% of patients having AML.
Skupina modificirane ITT populacije (engl. modified intent-to-treat, MITT) uključivala je 465 primatelja alogene HSCT, a 45% bolesnika imalo je akutnu mijeloičnu leukemiju (AML).
The modified-release tablets are round (diameter 8 mm) and convex.
Tablete s prilagođenim oslobađanjem okrugle su (promjera 8 mm) i ispupčene.
The monitoring and treatment schedule should be determined by the treating physician based on the individual patient’s response.
Nadležni liječnik treba odrediti praćenje i režim liječenja na temelju pojedinačnog odgovora bolesnika.
The monoclonal antibody delivers monomethyl auristatin E to the CD30-positive cancer cells, and once inside the cancer cells, it stops them from dividing, and the cancer cells eventually die.
Monoklonsko protutijelo dostavlja monometil auristatin E u stanice raka pozitivne na CD30, a kada uđe u stanice raka, zaustavlja njihovu diobu i stanice raka naposljetku umiru.
The monophosphate metabolite is subsequently converted to the active 5’-triphosphate form, ara-GTP.
Monofosfatni metabolit potom prelazi u aktivni 5’-trifosfatni oblik, ara-GTP.
The monophosphate metabolite is subsequently converted to the active 5’-triphosphate from, ara-GTP.
Monofosfatni metabolit potom prelazi u aktivni 5’-trifosfatni oblik, ara-GTP.
The more ‘white active tablets’ are missed and the closer the missed tablets are to the 4 yellow placebo tablets, the higher the risk of a pregnancy.
Što se više 'bijelih tableta s djelatnim tvarima' propusti i što su propuštene tablete bliže četirima žutim tabletama placeba, veći je rizik od trudnoće.
The morning dose should be taken at least 30 minutes before the morning meal, whereas the evening dose can be taken with or without food.
Jutarnju dozu treba uzimati najmanje 30 minuta prije doručka, dok se večernja doza može uzimati uz obrok ili bez obroka.
The most abundant circulating dexmedetomidine metabolites are two isomeric N- glucuronides.
Dva najzastupljenija metabolita deksmedetomidina u optoku su dva izomerna N-glukuronida.
The most abundant metabolites of tasimelteon have less than one- tenth of the binding affinity of the parent molecule for both the MT1 and MT2 receptors.
Najzastupljeniji metaboliti tazimelteona pokazuju manje od jedne desetine afiniteta vezanja ishodišne molekule i za receptore MT1 i receptore MT2.
The most abundant plasma metabolite was M1, which represented 21% of drug-related radioactivity (AUC) in circulation following single dose; it’s formed via oxidative metabolism predominantly by CYP2C8.
Najzastupljeniji metabolit u plazmi bio je M1, koji je činio 21% cirkulirajuće radioaktivnosti povezane s lijekom nakon primjene jednokratne doze; M1 se formira oksidativnim metabolizmom uglavnom putem CYP2C8.
The most appropriate MedDRA term is used to describe a certain reaction and its synonyms and related conditions.
Koristi se najprimjereniji MedDRA-in naziv za opisivanje određene reakcije i njegovi sinonimi i povezana stanja.
The most appropriate strategies to monitor the off label use within national territories
o najprikladnije strategije za nadzor primjene lijeka izvan odobrenih indikacija unutar teritorija pojedine države
The most clinically serious adverse event reported following multiple oral doses of  200 mg was hypotension which resolved following oral or intravenous fluid administration.
Klinički najozbiljniji štetni događaj prijavljen nakon više oralnih doza od ≥ 200 mg bila je hipotenzija, koja je prestala nakon peroralnog ili intravenskog davanja tekućine.
The most clinically serious adverse event reported following multiple oral doses of  200 mg was hypotension which resolved following oral or intravenous fluid administration.
Najozbiljnija klinička nuspojava zabilježena nakon višekratnih oralnih doza od  200 mg bila je hipotenzija koja je otklonjena peroralnim ili intravenskim davanjem tekućine.
The most common (≥ 20%) adverse reactions observed following treatment with axitinib were diarrhoea, hypertension, fatigue, decreased appetite, nausea, weight decreased, dysphonia, palmar- plantar erythrodysaesthesia (hand-foot) syndrome, haemorrhage, hypothyroidism, vomiting, proteinuria, cough, and constipation.
Najčešće (≥ 20%) nuspojave opažene nakon terapije aksitinibom bile su proljev, hipertenzija, umor, smanjenje teka, mučnina, smanjenje tjelesne težine, disfonija, sindrom palmarno-plantarne eritrodizestezije (sindrom šaka i stopala), krvarenje, hipotireoza, povraćanje, proteinurija, kašalj i konstipacija.
The most common ADR leading to discontinuation was rash (2.2% in the INTELENCE arm versus 0% in the placebo arm).
Najčešća nuspojava koja je dovodila do prekida liječenja bila je osip (2,2% u skupini koja je primala INTELENCE u odnosu na 0% u skupini na placebu).
The most common ADRs (≥ 50%) seen with Perjeta in combination with trastuzumab and docetaxel were diarrhoea, alopecia and neutropenia.
Najčešće nuspojave lijeka (≥ 50%) primijećene kada se Perjeta primjenjivala u kombinaciji s trastuzumabom i docetakselom bile su proljev, alopecija i neutropenija.
The most common adverse drug reactions (ADR) (> 30%) reported with vemurafenib include arthralgia, fatigue, rash, photosensitivity reaction, nausea, alopecia and pruritus.
Najčešće nuspojave (> 30%) prijavljene kod liječenja vemurafenibom uključuju artralgiju, umor, osip, fotosenzitivne reakcije, mučninu, alopeciju i pruritus.
The most common adverse drug reactions (ADRs) (≥ 10%) were akathisia and somnolence, which were dose-related up to 111 mg daily.
Najčešće nuspojave lijeka (≥ 10%) bile su akatizija i pospanost, koje su ovisile o dozi do 111 mg dnevno.
The most common adverse drug reactions (≥ 35%) reported during treatment with Dacogen are pyrexia, anaemia and thrombocytopaenia.
Najčešće nuspojave (≥ 35%) prijavljene tijekom liječenja Dacogenom bile su pireksija, anemija i trombocitopenija.
The most common adverse drug reactions in patients receiving Lonsurf that resulted in treatment discontinuation, dose reduction, dose delay, or dose interruption were neutropenia, general deterioration of health, anaemia, febrile neutropenia, fatigue, diarrhoea and dyspnoea.
Najčešće nuspojave u bolesnika koji su primali Lonsurf, a koje su imale za posljedicu prekid liječenja, smanjenje doze ili odgodu uzimanja doze, ili privremeni prekid uzimanja bile su neutropenija, opće pogoršanje zdravstvenog stanja, anemija, febrilna neutropenija, umor, proljev i dispneja.
The most common adverse drug reactions were eye pain and eye pruritus occurring in 1% to 2.0% of patients.
Najčešće nuspojave bile su bol u oku i svrbež oka, a pojavile su se u 1,0% do 2,0% bolesnika.
The most common adverse events in children and adolescents 6 to 17 years of age were: Nervous system disorders:
Najčešći štetni događaji kod djece i adolescenata u dobi od 6 do 17 godina bili su: Poremećaji živčanog sustava:
The most common adverse reaction associated with both IZBA and Travoprost 40 µg/mL eye drops, solution is hyperaemia.
Najčešća nuspojava povezana i s IZBOM i Travoprost 40 µg/ml kapima za oko, otopinom je hiperemija.
The most common adverse reaction leading to discontinuation of Zurampic was blood creatinine increased (0.8%).
Najčešća nuspojava koja je dovela do prekida primjene lijeka Zurampic bila je povišen kreatinin u krvi (0,8%).
The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %).
Umor je bio najčešća nuspojava prijavljena s većom incidencijom u bolesnika na umjereno emetogenoj kemoterapiji koji su uzimali aprepitant nego u bolesnika na standardnoj terapiji (1,4% u odnosu na 0,9%).
The most common adverse reaction reported by patients treated with Zalmoxis in clinical trial TK007 was acute GvHD.
Najčešća nuspojava prijavljena od strane bolesnika liječenih Zalmoxisom u kliničkom ispitivanju TK007 bila je akutni GvHD.
The most common adverse reaction was headache (occurred mostly in the initial phase), and the most serious adverse reaction was meningococcal sepsis.
Najčešća nuspojava bila je glavobolja (koja se uglavnom javljala u početnoj fazi liječenja), a najozbiljnija nuspojava bila je meningokokna sepsa.
The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn’s disease clinical studies with ustekinumab were nasopharyngitis and headache.
Najčešće prijavljene nuspojave (> 5%) u kontroliranim razdobljima kliničkih ispitivanja psorijaze, psorijatičnog artritisa i Crohnove bolesti kod odraslih bolesnika s ustekinumabom bile su nazofaringitis i glavobolja.
The most common adverse reactions (all grades, ≥20% incidence) reported at least 2% greater incidence for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency were leucopenia, diarrhoea, neutropenia, proteinuria, increased aspartate aminotransferase (AST), stomatitis, fatigue, thrombocytopenia, increased alanine aminotransferase (ALT), hypertension, weight loss, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, and headache (see Table 1).
Najčešće nuspojave (svih stupnjeva, incidencija ≥ 20%) čija je prijavljena incidencija u skupini koja je primala protokol ZALTRAP/FOLFIRI bila najmanje 2% veća od one u skupini koja je primala protokol placebo/FOLFIRI, navedene prema učestalosti u padajućem nizu, bile su leukopenija, proljev, neutropenija, proteinurija, povišene vrijednosti aspartat aminotransferaze (AST), stomatitis, umor, trombocitopenija, povišene vrijednosti alanin aminotransferaze (ALT), hipertenzija, gubitak tjelesne težine, smanjen tek, epistaksa, bol u abdomenu, disfonija, povišene vrijednosti kreatinina u serumu i glavobolja (vidjeti Tablicu 1).
The most common adverse reactions (experienced by at least 10 % of the patients) of any grade in the RCC and STS trials included: diarrhoea, hair colour change, skin hypopigmentation, exfoliative rash, hypertension, nausea, headache, fatigue, anorexia, vomiting, dysgeusia, stomatitis, weight decreased, pain, elevated alanine aminotransferase and elevated aspartate aminotransferase.
Najčešće nuspojave (koje je doživjelo najmanje 10% bolesnika) bilo kojeg stupnja u RCC i STS ispitivanjima uključivale su: proljev, promjenu boje kose, hipopigmentaciju kože, osip s ljuštenjem, hipertenziju, mučninu, glavobolju, slabost, anoreksiju, povraćanje, disgeuziju, stomatitis, smanjenje tjelesne težine, bol, povišene razine alanin aminotransferaze te povišene razine aspartat aminotransferaze.
The most common adverse reactions (incidence ≥ 20%) of ONIVYDE+5FU/LV were: diarrhoea, nausea, vomiting, decreased appetite, neutropenia, fatigue, asthenia, anaemia, stomatitis and pyrexia.
Najčešće nuspojave (incidencija ≥ 20%) primjene lijeka ONIVYDE+5FU/LV bile su: proljev, mučnina, povraćanje, smanjen apetit, neutropenija, umor, astenija, anemija, stomatitis i vrućica.
The most common adverse reactions (incidence ≥10%) for patients treated with Tecfidera were flushing and gastrointestinal events (i.e. diarrhoea, nausea, abdominal pain, abdominal pain upper).
Najčešće nuspojave (incidencija ≥10%) za bolesnike liječene Tecfiderom su bile crvenilo uz osjećaj vrućine i gastrointestinalne smetnje (npr. proljev, mučnina, bol u trbuhu, bol u gornjem dijelu trbuha).
The most common adverse reactions (incidence ≥10%) were diarrhoea, nausea, abdominal pain, cholelithiasis, injection site reactions, hyperglycaemia, diabetes mellitus, fatigue and glycosylated haemoglobin increased.
Najčešće nuspojave (incidencija ≥10%) bile su proljev, mučnina, bolovi u abdomenu, kolelitijaza, reakcije na mjestu primjene, hiperglikemija, šećerna bolest, umor i povišenje razine glikoziliranog hemoglobina.